MilliporeSigma
  • Home
  • Search Results
  • Aripiprazole adjunct treatment in bipolar I or II disorder, depressed state: a 2-year clinical study.

Aripiprazole adjunct treatment in bipolar I or II disorder, depressed state: a 2-year clinical study.

The Journal of nervous and mental disease (2014-12-24)
Rao N Malempati
ABSTRACT

The symptomatic course of bipolar disorder (BPD) is chronic and dominated by depression. As recurrence rates are high, maintenance therapy is required. Although efficacious, mood stabilizers may be hampered by poor adherence, and second-generation antipsychotic medications may be associated with weight gain and metabolic abnormalities. There is evidence to suggest that aripiprazole is beneficial in major depressive disorder and BPD with depression. We therefore investigated 2-year clinical outcomes with aripiprazole adjunct therapy at 5 to 15 mg once daily alongside a mood stabilizer in 40 patients with BPD. All patients experienced marked improvements in Montgomery-Åsberg Depression Rating Scale scores by 6 weeks and substantial reductions in Clinical Global Impressions Scale scores by 6 months. All patients were able to return to optimal or premorbid functioning by 6 months to 1 year. By 1 year, all patients made a complete functional recovery on the Sheehan Disability Scale. Improvements were maintained on all measures up to 2 years. There were minimal adverse events, all of which decreased during therapy. Our findings indicate that aripiprazole adjunct treatment is safe and effective as an acute and maintenance therapy for BPD. However, the findings will need to be replicated by larger studies.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Lithium, ribbon, thickness × W 0.75 mm × 45 mm, 99.9% trace metals basis
Sigma-Aldrich
Lithium, ribbon, thickness × W 0.38 mm × 23 mm, 99.9% trace metals basis
Sigma-Aldrich
Lithium, ribbon, thickness × W 1.5 mm × 100 mm, 99.9% trace metals basis
Sigma-Aldrich
Lithium, wire (in mineral oil), diam. 3.2 mm, 99.9% trace metals basis
Sigma-Aldrich
Lithium, ribbon, thickness × W 0.75 mm × 19 mm, 99.9% trace metals basis
Sigma-Aldrich
Lithium, granular, 4-10 mesh particle size, high sodium, 99% (metals basis)
Sigma-Aldrich
Lithium, rod, diam. 12.7 mm, 99.9% trace metals basis
Sigma-Aldrich
Lithium, wire, diam. 3.2 mm, in mineral oil, ≥98%
Sigma-Aldrich
Lithium, granular, 99% trace metals basis
Aripiprazole, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Lithium, foil, not light tested, 38x500mm, thickness 0.20mm, as rolled, 99.9%
Lithium, foil, not light tested, 38x200mm, thickness 0.20mm, as rolled, 99.9%
Lithium, foil, 25x100mm, thickness 0.6mm, as rolled, 99.9%